Search clinical trials for: Cyclophosphamide Busilvex

Total 3769 results

Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Leukemia, Myelocytic, Acute

United States
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma (HR MB-5)

High-risk Medulloblastoma

France
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Lymphoma | Leukemia | HIV

United States
The Netherlands Cancer Institute

Terminated

Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD

Breast Cancer

Netherlands
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Masonic Cancer Center, University of Minnesota

Completed

Stem Cell Transplantation for Hurler

Mucopolysaccharidosis I | Mucopolysaccharidosis VI | Mannosidosis | Mucolipidosis Type II (I-cell Disease)

United States
medac GmbH
Syneos Health; Celerion; Venn Life Sciences

Completed

Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

Bone Marrow Failure Syndromes | Inborn Errors of Metabolism | Primary Immunodeficiencies | Haemoglobinopathies

Poland, Czechia, Germany, Italy
Masonic Cancer Center, University of Minnesota

Completed

Stem Cell Transplant for Inborn Errors of Metabolism

Niemann-Pick Disease | Wolman Disease | Adrenoleukodystrophy | Batten Disease | Metachromatic Leukodystrophy | GM1 Gangliosidosis | Fucosidosis | Globoid Cell Leukodystrophy | Gaucher's Disease | Tay Sachs Disease | Sandhoff Disease

United States
Masonic Cancer Center, University of Minnesota

Completed

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Not yet recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Peking University People's Hospital

Recruiting

ATG Plus Low-dose PT-Cy for GVHD Prevention

Hematologic Malignancy

China
Priv.-Doz. Dr. med. Joachim Rom

Completed

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

Epithelial Ovarian Cancer

Germany
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML)

Myeloid Hematological Malignancies

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Umbilical Cord Blood Transplant for Congenital Pediatric Disorders (UCB)

Congenital Pediatric Disorders

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Malignant Brain Neoplasm | Recurrent Malignant Brain Neoplasm | Refractory Malignant Brain Neoplasm

United States
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Unresectable Breast Carcinoma

United States
Assiut University

Active, not recruiting

Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Lupus Nephritis

Egypt
Children's Hospital Los Angeles
Lucile Packard Children's Hospital

Terminated

Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells

Metabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

Anemia, Aplastic

United States
Beijing 302 Hospital

Not yet recruiting

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Hematological Malignancies | Graft-versus-host Disease
Sanofi

Completed

Study of Docetaxel in Breast Cancer Patients

Breast Neoplasms

Italy
Mayo Clinic

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 and other conditions

United States
Richard Wu
Iovance Biotherapeutics, Inc.

Active, not recruiting

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Locally Advanced Melanoma | Stage IV Melanoma | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Triple-Negative Breast Carcinoma | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

B Acute Lymphoblastic Leukemia

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
Masonic Cancer Center, University of Minnesota
National Marrow Donor Program

Completed

Stem Cell Transplant for Hemoglobinopathy

Sickle Cell Disease | Thalassemia | Severe Congenital Neutropenia | Diamond-Blackfan Anemia | Shwachman-Diamond Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
St. Petersburg State Pavlov Medical University

Recruiting

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)

Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloid Leukemia, Acute

Russian Federation
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)

Recruiting

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

DOCK8 Deficiency

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

Chronic Granulomatous Disease

United States
UNC Lineberger Comprehensive Cancer Center
University Cancer Research Fund at Lineberger Comprehensive Cancer Center

Recruiting

CD30 CAR for CD30+ NSGCT

Nonseminomatous Germ Cell Tumor | Germ Cell Tumor

United States
University of Liege
Belgian Hematological Society

Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (HLA)

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloproliferative Disorder | Chronic Lymphoid Leukemia | Acute Myeloid Leukemia in Remission | Myeloproliferative Syndrome | Chronic Myeloid Leukemia in Remission | Acute Lymphoid Leukemia in Remission

Belgium
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

Recurrent Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Refractory Liver Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Soonchunhyang University Hospital

Completed

BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma (CISL)

Non-hodgkin Lymphoma

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI); CytoImmune Therapeutics

Recruiting

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer... and other conditions

United States
Second Affiliated Hospital, School of Medicine,...
Carbiogene Therapeutics Co. Ltd.

Recruiting

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
University of Utah

Terminated

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Primary Myelofibrosis | Anemia | Thrombocytopenia | Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | IDH2 Gene Mutation | IDH1 Gene Mutation | Secondary Myelofibrosis | ASXL1 Gene Mutation | EZH2 Gene Mutation

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

Systemic Scleroderma

United States
Guenther Koehne

Not yet recruiting

CD34+ Transplants for Leukemia and Lymphoma

Leukemia, Myeloid, Acute | Leukemia, Lymphocytic, Acute

United States

Search clinical trials for: Cyclophosphamide Busilvex

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations